These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30968147)

  • 1. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
    Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
    Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect Radioiodination of DARPin G3 Using N-succinimidyl-
    Vorobyeva A; Schulga A; Rinne SS; Günther T; Orlova A; Deyev S; Tolmachev V
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.
    Deyev S; Vorobyeva A; Schulga A; Proshkina G; Güler R; Löfblom J; Mitran B; Garousi J; Altai M; Buijs J; Chernov V; Orlova A; Tolmachev V
    Mol Pharm; 2019 Mar; 16(3):995-1008. PubMed ID: 30608701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
    Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
    Contrast Media Mol Imaging; 2018; 2018():6930425. PubMed ID: 29977173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.
    Goldstein R; Sosabowski J; Livanos M; Leyton J; Vigor K; Bhavsar G; Nagy-Davidescu G; Rashid M; Miranda E; Yeung J; Tolner B; Plückthun A; Mather S; Meyer T; Chester K
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):288-301. PubMed ID: 25391547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
    Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
    Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with
    Lindbo S; Garousi J; Mitran B; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Tolmachev V
    Mol Pharm; 2018 Jul; 15(7):2674-2683. PubMed ID: 29865791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.
    Vorobyeva A; Bezverkhniaia E; Konovalova E; Schulga A; Garousi J; Vorontsova O; Abouzayed A; Orlova A; Deyev S; Tolmachev V
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33066684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.
    Deyev SM; Vorobyeva A; Schulga A; Abouzayed A; Günther T; Garousi J; Konovalova E; Ding H; Gräslund T; Orlova A; Tolmachev V
    Int J Biol Macromol; 2020 Feb; 145():216-225. PubMed ID: 31863835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sortase-Mediated Site-Specific Conjugation and
    Fay R; Törő I; Schinke AL; Simic B; Schaefer JV; Dreier B; Plückthun A; Holland JP
    Mol Pharm; 2022 Oct; 19(10):3576-3585. PubMed ID: 35434995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
    Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
    J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.
    Garousi J; Lindbo S; Borin J; von Witting E; Vorobyeva A; Oroujeni M; Mitran B; Orlova A; Buijs J; Tolmachev V; Hober S
    Eur J Pharm Biopharm; 2019 Jan; 134():37-48. PubMed ID: 30408518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifunctional superparamagnetic nanoparticles conjugated with fluorescein-labeled designed ankyrin repeat protein as an efficient HER2-targeted probe in breast cancer.
    Li DL; Tan JE; Tian Y; Huang S; Sun PH; Wang M; Han YJ; Li HS; Wu HB; Zhang XM; Xu YK; Wang QS
    Biomaterials; 2017 Dec; 147():86-98. PubMed ID: 28938164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal composition and position of histidine-containing tags improves biodistribution of
    Vorobyeva A; Schulga A; Konovalova E; Güler R; Löfblom J; Sandström M; Garousi J; Chernov V; Bragina O; Orlova A; Tolmachev V; Deyev SM
    Sci Rep; 2019 Jun; 9(1):9405. PubMed ID: 31253840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with
    Larkina M; Plotnikov E; Bezverkhniaia E; Shabanova Y; Tretyakova M; Yuldasheva F; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Garousi J; Gräslund T; Belousov M; Tolmachev V; Deyev S
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion.
    Deyev SM; Oroujeni M; Garousi J; Gräslund T; Li R; Rosly AHB; Orlova A; Konovalova E; Schulga A; Vorobyeva A; Tolmachev V
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
    Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
    Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of the optimal macrocyclic chelators for labeling with
    von Witting E; Garousi J; Lindbo S; Vorobyeva A; Altai M; Oroujeni M; Mitran B; Orlova A; Hober S; Tolmachev V
    Eur J Pharm Biopharm; 2019 Jul; 140():109-120. PubMed ID: 31082509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.